Logo

PharmaShots Weekly Snapshots (May 02-06, 2022)

Share this
PharmaShots Weekly Snapshots (May 02-06, 2022)

PharmaShots Weekly Snapshots (May 02-06, 2022)

Orion Entered into an Agreement with Jemincare to Develop & Commercialize JMKX000623 for the Treatment of Pain

Published: May 6, 2022 | Tags: Orion, Jemincare, JMKX000623, Pain

Amylyx Publishes Results of AMX0035 in P-II (CENTAUR) Trial for the Treatment of Amyotrophic Lateral Sclerosis in Muscle & Nerve

Published: May 6, 2022 | Tags: Amylyx, AMX0035, P-II, CENTAUR Trial, Amyotrophic Lateral Sclerosis, Muscle, Nerve

Palisade Bio and Newsoara’s LB1148 Receive NMPA’s Clearance to Initiate P-III Trial to Improve Bowel Function After Abdominal Surgery

Published: May 6, 2022 | Tags: Palisade Bio, Newsoara, LB1148, NMPA, Clearance, P-III Trial, Bowel Function, Abdominal Surgery

Zai Lab Partner argenx Report Results of Vyvgart (efgartigimod alfa-fcab) P-III (ADVANCE) Trial for Primary Immune Thrombocytopenia

Published: May 6, 2022 | Tags: Zai Lab, argenx, Vyvgart, efgartigimod alfa-fcab, P-III, ADVANCE Trial, Primary Immune Thrombocytopenia

Scilex Presents Results of Semdexa (SP-102) in P-III (SEMDEXA) Trial for the Treatment of Sciatica Pain Management at ASIPP 2022

Published: May 6, 2022 | Tags: Scilex Presents Results of Semdexa (SP-102) in P-III (SEMDEXA) Trial for the Treatment of Sciatica Pain Management at ASIPP 2022

Biogen Entered into a License Agreement with MedRhythms to Develop and Commercialize MR-004 for the Treatment of Gait Deficits in Multiple Sclerosis

Published: May 6, 2022 | Tags: Biogen, MedRhythms, MR-004, Gait Deficits, Multiple Sclerosis

AstraZeneca’s Farxiga (dapagliflozin) Meet its Primary Endpoints in the P-III (DELIVER) Trial for Heart Failure with a Preserved Ejection Fraction

Published: May 5, 2022 | Tags: AstraZeneca, Farxiga, P-III, DELIVER Trial, Heart Failure, Preserved Ejection Fraction

Byondis Entered into a Multiple Agreement with medac to Commercialize Trastuzumab Duocarmazine (SYD985) for the Treatment of Cancer

Published: May 5, 2022 | Tags: Byondis, medac, Trastuzumab Duocarmazine, SYD985, Cancer

Novartis Updated Exploratory OS Analysis of Kisqali (ribociclib) in P-III (MONALEESA-3) Trial for the Treatment of HR+/HER2- Advanced Breast Cancer

Published: May 5, 2022 | Tags: Novartis, Kisqali, ribociclib, P-III, MONALEESA-3 Trial, HR+, HER2-, Breast Cancer

Incyte’s Jakavi (ruxolitinib) Receives EC’s Approval as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

Published: May 5, 2022 | Tags: Incyte, Jakavi, ruxolitinib, EC, Approval, Post-Steroid, Acute, Chronic, Graft-Versus-Host Disease

Jazz Entered into an Exclusive License Agreement with Sumitomo Pharma to Develop and Commercialize DSP-0187 for the Treatment of Sleep Disorders

Published: May 5, 2022 | Tags: Jazz, Sumitomo Pharma, DSP-0187, Sleep Disorder

Amphista Signs a License Agreement with BMS to Discover & Develop Targeted Protein Degradation Therapies Using Eclipsys TPD Platform

Published: May 5, 2022 | Tags: Amphista, BMS, Protein Degradation Therapies

BeiGene’s Blincyto (blinatumomab) Receives the NMPA’s Approval for Pediatric Patients with Relapsed or Refractory B-Cell Precursor ALL

Published: May 4, 2022 | Tags: BeiGene, Blincyto, blinatumomab, NMPA, Approval, Pediatric Patients,  Relapsed or Refractory, B-Cell Precursor ALL

The US FDA Issued Complete Response Letter to Hutchmed’s Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

Published: May 4, 2022 | Tags: US, FDA, Complete Response Letter, Hutchmed, Surufatinib, Advanced Neuroendocrine Tumors

Horizon Reports Results of HZN-4920 in P-II Study for Rheumatoid Arthritis

Published: May 4, 2022 | Tags: Horizon, HZN-4920, P-II, Rheumatoid Arthritis

iSono Health’s ATUSA System Receives the US FDA’s Approval as the World’s First Automated and Wearable 3D Breast Ultrasound

Published: May 4, 2022 | Tags: iSono Health, ATUSA, US FDA, Breast Imaging

Hepion Collaborates with HepQuant for P-IIb Study of Rencofilstat (CRV431) in NASH

Published: May 4, 2022 | Tags: Hepion, HepQuant, P-IIb,  Rencofilstat, CRV431, NASH

Vertex Reports the FDA’s Clinical Hold on P-I/II Study of VX-880 for the Treatment of Type 1 Diabetes

Published: May 4, 2022 | Tags: Vertex, FDA, Clinical Hold, P-I/II Study, VX-880, Type 1 Diabetes

Ipsen’s Cabometyx Receives EC’s Approval as a 2L treatment for Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Published: May 3, 2022 | Tags: Ipsen, Cabometyx, EC, Approval, Radioactive, Iodine-Refractory, Differentiated Thyroid Cancer

Genesis Entered into a Collaboration with Lilly to Discover Novel Therapies for up to Five Targets

Published: May 3, 2022 | Tags: Genesis, Lilly, Novel Therapies, AI Drug Discovery Platform

Denali Partner Sanofi Reports the Patient Dosing in P-II (HIMALAYA) Study of SAR443820 for the Treatment of Amyotrophic Lateral Sclerosis

Published: May 3, 2022 | Tags: Denali, Sanofi, P-II, HIMALAYA Study, SAR443820, Amyotrophic Lateral Sclerosis

Apellis Presents 18-Month Results of Pegcetacoplan in P-III (DERBY) and (OAKS) Studies for the Treatment of Geographic Atrophy at ARVO 2022

Published: May 3, 2022 | Tags: Apellis, Pegcetacoplan, P-III, DERBY, OAKS Studies, Geographic Atrophy, ARVO, 2022

UCB Publishes Results of Fintepla (fenfluramine) in the P-III Trial for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in JAMA Neurology

Published: May 3, 2022 | Tags: UCB, Fintepla, fenfluramine, P-III Trial, Seizures, Lennox-Gastaut Syndrome, JAMA Neurology

Gilead Entered into a Research Collaboration with Dragonfly to Develop Natural Killer Cell Engagers for Oncology and Inflammation Indications

Published: May 3, 2022 | Tags: Gilead, Dragonfly, Natural Killer Cell Engagers, Oncology, Inflammation Indications

Sage and Biogen Initiate Rolling Submission of NDA to US FDA for Zuranolone to Treat Major Depressive Disorder

Published: May 2, 2022 | Tags: Sage Therapeutics, Biogen, NDA, US FDA, Zuranolone, Major Depressive Disorder

CytoSorbents Reports the First Patient Enrollment of DrugSorb-ATR Antithrombotic Removal System in the (STAR-D) Trial During Cardiac Surgery

Published: May 2, 2022 | Tags: CytoSorbents, DrugSorb-ATR Antithrombotic Removal System, STAR-D Trial, Cardiac Surgery

Abbott Reports Results of TactiCath SE in (PERSIST-END) Study for the Treatment of Persistent Atrial Fibrillation

Published: May 2, 2022 | Tags: Abbott, TactiCath SE, PERSIST-END Study, Persistent Atrial Fibrillation

Horizon’s Uplizna (inebilizumab) Receives EC’s Approval for the Treatment of Neuromyelitis Optica Spectrum Disorder

Published: May 2, 2022 | Tags: Horizon, Uplizna, inebilizumab, EC, Approval, Neuromyelitis Optica Spectrum Disorder

Merck’s Keytruda (pembrolizumab) Receives EC’s Approval for MSI-H or dMMR Tumors in Five Different Types of Cancer

Published: May 2, 2022 | Tags: Merck, Keytruda, pembrolizumab, EC, Approval, MSI-H, dMMR Tumors, Cancer

Ionova Entered into a Clinical Trial Collaboration with MSD to Evaluate INV-1120 + Keytruda (pembrolizumab) for Advanced Solid Tumors

Published: May 2, 2022 | Tags: Ionova, MSD, INV-1120, Keytruda (pembrolizumab) for Advanced Solid Tumors

Related Post: PharmaShots Weekly Snapshots (April 25-29, 2022)


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions